Schering-Plough Articles
Public Citizen says Pharma is biggest defrauder of US federal government under False Claims Act
20 December 2010
Merck & Co’s 2nd-qtr 2010 profits plunge 52% on S-P buy costs, but still beat expectations
2 August 2010
Merck & Co 1st-qtr 2010 earnings better-than-expected but full-year forecast seen as cautious
5 May 2010
Merck & Co’s integrated pipeline has over 20 drugs and vaccines in late-stage development
2 March 2010
Merck & Co rises 2.3% as it beats 4th quarter 2009 sales forecast, boosted by Schering-Plough
17 February 2010
M&A - the trials and tribulations, as viewed by former Schering-Plough CEO Fred Hassan
17 February 2010
Merck & Co returns rights to anti-fungal drug to Anacor
15 February 2010
Burst of M&A activity in pharma during 2009 led by mega-deals from Pfizer/Wyeth and Merck & Co/S-P
4 February 2010
Pharmaceutical M&A deals in 2009
4 February 2010
Setback for Merck & Co as vicriviroc disappoints in Ph III
22 January 2010
Merck & Co extends biotech reach with acquisition of UK’s Avecia
18 December 2009
Russia's hepatitis C virus drug market set to grow 9% annually, reaching $327 million by 2013
3 December 2009
Big Pharma seeks to insulate itself from impact of ‘patent cliff’
24 November 2009
Corporate R&D investment in 2008: a global increase with EU companies leading USA and Japan; Pharma/biotech top sectors
16 November 2009
Merck & Co remains confident in Zetia and Vytorin, despite studying questioning the drugs
16 November 2009
Former S-P chief Fred Hassan joins Bausch & Lomb board of directors
13 November 2009
Bristol-Myers Squibb gains rights to Alder’s rheumatoid arthritis biologic for up to $1 billion
11 November 2009
Merck & Co - now world’s No 2 drugmaker - upbeat about new operation post Schering-Plough merger; but what about J&J?
5 November 2009
With completion of Merck & Co/Schering-Plough merger, Haruo Naito confirmed as new president of IFPMA
4 November 2009
Biosimilars of TNF-alpha inhibitors stand to erode over $9 billion in brand sales in USA and Europe by 2018
4 November 2009
One time gain triples Merck & Co’s 3rd quarter 2009 earnings, beating forecasts; EU clears S-P deal
23 October 2009
Cancer drugs emerging as top driver of specialty drug spending
12 October 2009
UCB’s Cimzia approved for RA in Europe
7 October 2009
Highlights of research presented at ICAAC
15 September 2009
Public Citizen’s HRG slams Pfizer’s $2.3 billion settlement as not enough to deter bad behaviour by Pharma
9 September 2009
SkyePharma slumps on US delay for Flutiform
2 September 2009
Merck wins Singulair patent infringement law suit with Teva
20 August 2009
Schering-Plough gets US approval for Saphris
17 August 2009
FDA Committee backs Schering-Plough’s Saphris
3 August 2009
EMEA accepts MAA for S-P's Sycrest for review
4 June 2009
J&J continues opposition to Merck/S-P merger
28 May 2009
AVI appoints Paul Medeiros CBO
21 May 2009
S-P begins enrollment for heart bypass trial
20 May 2009
UPDATE: Ligand's 1st-qtr 2009 loss deepens 30%
12 May 2009
Ligand narrows loss on rocketing revenue
8 May 2009
Vertex' telaprevir achieves unprecedented SVR
27 April 2009
Locteron shows better AE profile than PEG-Intron
24 April 2009
CHMP meeting sees good news for AZ, but not for Teva
24 April 2009
Merck & Co 1st-qtr profit slumps 57%
21 April 2009
Schering-Plough profits beat forecasts
21 April 2009
AZ eyeing up small European firms
15 April 2009
J&J/S-P's Simponi cleared in Canada
14 April 2009
Integrilin disappoints in EARLY ACS study
9 April 2009
S-P settles Mylan Clarinex dispute
9 April 2009
FDA expands indication for S-P hep C combo
30 March 2009
Merck & Co updates on credit facility
30 March 2009
S-P withdraws Cylatron MAA
30 March 2009
Study shows no higher cancer risk with Vytorin
27 March 2009
Advantages of telaprevir- and boceprevir-based regimens
23 March 2009
S-P to pay $165M to settle disclosure law suit
23 March 2009
Stock Commentary - New York week to Mar 16, 2009
23 March 2009
S-P's TRA meets Ph II study endpoints
23 March 2009
Stock Commentary - Europe - week to Mar 9, 2009
16 March 2009
Stock Commentary - New York week to Mar 9, 2009
16 March 2009
$60M exit package for S-P CEO Hassan?
16 March 2009
Temodar gets UK/US appro in IV form
16 March 2009
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
